Author:
Mizoguchi Kosuke,Nakamura Yoichi,Sano Kazumi,Sato Shuntaro,Ikegami Yoji,Motoshima Kohei,Takemoto Shinnosuke,Ogawara Daiki,Senju Hiroaki,Sugasaki Nanae,Ikeda Takaya,Yamaguchi Hiroyuki,Nakatomi Katsumi,Fukuda Minoru,Izumikawa Koichi,Mukae Hiroshi
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference11 articles.
1. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388
2. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128
3. Zhao YY, Li S, Zhang Y et al (2011) The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med Oncol 28:697–702
4. Hirano S, Sano K, Takeda Y et al (2012) The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor (EGFR) mutation. Gan To Kagaku Ryoho 39:1501–1506
5. Nakamura Y, Sano K, Soda H et al (2012) Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol 5:1404–1409
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献